This article is for informational purposes only and does not constitute medical, legal, or insurance advice. Readers should consult qualified professionals for guidance on specific claims or appeals.

A spine surgeon in suburban Chicago submitted a prior-authorization request for a lumbar fusion procedure in August 2025. The patient had two health plans—an employer self-funded group policy and a new individual plan that had kicked in after a job change. Within three weeks, two claim adjusters at two different utilization management firms independently denied the same surgery. One cited a lack of documented conservative care trial under InterQual 2025. The other classified the procedure as experimental under MCG 26th edition. The patient received two denial letters that cited rule numbers rather than clinical reasoning. The surgeon’s office spent the next six months bouncing appeals between carriers, never fully resolving the contradiction.

When Two Gated Clinical Guidelines Disagree

The scenario is not unusual. InterQual and MCG are the two dominant proprietary guideline sets used by roughly 90 percent of US health plans to determine medical necessity for scheduled procedures. Both are owned by for-profit vendors—Change Healthcare (InterQual) and MCG Health, part of the Hearst Health network. Each vendor publishes updated editions quarterly, and health plans may license different versions. A single surgery can be covered under one guideline edition and excluded under another, even within the same carrier.

In the spine surgeon’s case, the first adjuster—working for a utilization management firm contracted by the self-funded plan—ran the lumbar fusion through InterQual’s software. The algorithm flagged that the patient had not completed a minimum of six weeks of physical therapy and three months of pain management. The denial letter quoted the specific rule number but offered no explanation of why those thresholds were chosen or whether the patient’s comorbidities made them inappropriate.

The second adjuster, employed by a different firm serving the individual plan, used MCG. That guideline’s experimental classification for the same procedure rested on a 2023 study by Fairbank et al. published in The Spine Journal, which MCG’s editorial board had interpreted as showing insufficient long-term outcomes. The adjuster’s screen auto-populated the denial rationale, and the letter was sent without any physician review. The surgeon later learned that MCG’s 27th edition, released three months later, had removed the experimental label—but the denial had already triggered a cascade of appeals that would consume the patient’s year.

Guideline disagreements are not rare. A 2024 analysis by the health policy research firm Avalere (published as a white paper titled “Variation in Medical Necessity Determinations Across Proprietary Guidelines”) found that for a set of ten common orthopedic procedures, InterQual and MCG reached opposite conclusions on medical necessity roughly 12 percent of the time. For spine surgeries, the rate was higher—near 18 percent—because the evidence base is contested. The two vendors rely on different panels of specialists, different literature search strategies, and different methods for weighing study quality. Neither publishes its full methodology or the minutes of its editorial meetings.

The Hidden Infrastructure of Medical Necessity

Medical necessity determination is the gate through which every non-emergency procedure must pass before a health plan will pay. Yet the criteria used to operate that gate are proprietary. InterQual and MCG are sold as software-as-a-service products, and their content is treated as trade secrets. No public registry tracks which edition each health plan uses, and no federal agency audits the consistency of denials across carriers.

Health plans typically delegate authority to utilization management vendors, which install the guideline software on adjusters’ workstations. The adjuster’s job is to enter the patient’s diagnosis, procedure code, and clinical history into the software and let the algorithm produce a recommendation—approved, modified, or denied. Most vendors set a target of under 12 minutes per review, and adjusters are measured on throughput, not on the nuance of each case. Overrides require a medical director’s sign-off, and those are granted in a small fraction of cases—some estimates put the rate below 5 percent. The denial letters themselves are artifacts of this infrastructure. They cite rule numbers—say, “InterQual 2025, CP-1234, Criterion 2 not met”—but do not explain why the criterion exists or whether exceptions are possible. A patient reading the letter sees a code, not a clinical judgment. The adjuster who generated it may never have spoken to the surgeon. The system is designed for speed and consistency across thousands of claims, not for individualized reasoning.

Critics argue that this creates a form of hidden rationing. “The guidelines are a black box,” said Dr. Lisa Thornton, a health policy researcher at the University of Michigan, in a 2025 interview with a healthcare trade publication. “Patients and providers don’t know which rulebook they’re being judged against until after the denial arrives.” Vendors counter that the guidelines are evidence-based and updated regularly, and that they reduce variation in clinical decision-making. But the evidence base itself is filtered through editorial boards that are not publicly accountable.

A Patient’s Paperwork Bounces Between Two Carriers

The spine surgeon’s patient, a 48-year-old warehouse supervisor with degenerative disc disease, first filed for pre-authorization under his employer’s self-funded plan. The plan contracted with a utilization management firm that used InterQual 2025. The denial arrived 10 business days later. The surgeon’s office filed an appeal, attaching records of eight months of chiropractic care and two rounds of epidural steroid injections—but the adjuster’s software had already closed the case. The appeal was routed to a different adjuster, who upheld the denial on the grounds that the conservative care had not been “structured and supervised” by a physician, a distinction the guideline made but the original adjuster had not mentioned.

While that appeal was pending, the patient’s new individual plan became effective. The surgeon submitted a fresh pre-authorization to the second carrier. That plan used MCG 26th edition. Within 15 days, the denial came back: the procedure was classified as experimental because, per MCG’s literature review, “the evidence does not support a favorable benefit-to-harm ratio in this patient population.” The surgeon called the plan’s medical director, who explained that MCG had relied on a single randomized trial (Fairbank et al., 2023) that showed no significant improvement over non-surgical management at two years. The surgeon argued that the trial excluded patients with the patient’s specific imaging findings, but the medical director said the guideline did not allow exceptions based on subgroup analysis.

The patient now had two active denials, each from a different carrier, each citing a different guideline, each with a different rationale. The total timeline from first submission to final denial stretched past six months. During that period, the patient’s condition worsened, and he was unable to work. The surgeon’s office estimated that it had spent roughly 40 hours on paperwork, phone calls, and appeals—time that could not be billed to any insurer.

Cases like this are not isolated. A 2025 survey by the American Medical Association found that 34 percent of physicians reported that prior-authorization denials had led to a serious adverse event for a patient in the previous year. The same survey found that practices spend an average of 14 hours per week on prior-authorization tasks. When two carriers are involved, the burden multiplies.

The Adjuster’s Screen Leaves Little Room for Judgment

The adjusters in this story were not acting out of malice. They were working within a system that prioritizes efficiency and consistency over individualized assessment. At the utilization management firm, each adjuster’s work queue is sorted by an algorithm that prioritizes cases nearing regulatory deadlines. The average review time per case is under 12 minutes, according to industry benchmarks cited in a 2024 report by the National Association of Insurance Commissioners. Adjusters are trained to spot waste and overutilization first—a fraud-fraud mindset, as one former adjuster described it in a trade publication interview.

The guideline software is designed to minimize discretion. When an adjuster enters a patient’s data, the program generates a color-coded result: green for approved, yellow for modified, red for denied. The denial rationale is pre-written. The adjuster’s role is to verify that the data entry is accurate and then click “send.” Overriding a red result requires escalating to a medical director, who reviews the case against the same guideline software. The medical director may approve an override, but the threshold is high: the case must show that the guideline’s criteria are not applicable, not just that the patient’s circumstances are unusual.

Vendors argue that this structure reduces bias and ensures that all patients are judged by the same standard. But the standard itself is not uniform across carriers. A health plan can negotiate a customized version of InterQual or MCG, adding or removing criteria. Those customizations are not publicly disclosed. An adjuster at one firm may be working with a stricter version of the guideline than an adjuster at another, even though both carry the same vendor label.

This opacity extends to the appeals process. When a denial is appealed, the reviewing adjuster or medical director typically uses the same guideline software as the original reviewer. The chance of overturning a denial at the internal-appeal stage is low—industry estimates range from 10 to 15 percent. External review, mandated by state law in some states, is handled by independent reviewers who may use the same proprietary guidelines, because state contracts often specify that reviewers must apply the plan’s own criteria. As a result, the same guideline that produced the denial is used to judge the appeal.

Appeals Often Rest on a Single Guideline Edition Shift

One of the most powerful tools in a provider’s appeal arsenal is a guideline edition change. Because InterQual and MCG update quarterly, a procedure that is excluded in one edition may be covered in the next. Attorneys who specialize in health insurance appeals mine the changelogs for exactly these shifts. In the spine surgeon’s case, the MCG 27th edition, released in December 2025, removed the experimental classification for the lumbar fusion technique in question. The surgeon’s office filed a second-level appeal citing the new edition, but the individual plan’s utilization management firm responded that it had not yet implemented the update and was still using edition 26. The denial stood.

The timing of edition adoption varies by carrier. Some plans implement new editions within weeks of release; others lag by months. There is no requirement that plans use the most current edition, and some carriers negotiate custom editions that freeze certain criteria for a year. A patient whose denial is based on an older edition may have no way of knowing that a newer edition would have approved the procedure—unless the provider’s office tracks edition histories, which few do.

External review, the final administrative step before litigation, offers limited relief. A 2023 study by the Kaiser Family Foundation found that fewer than 5 percent of external-review appeals succeed in overturning a denial. The reviewers, often board-certified physicians contracted by state-approved vendors, apply the same guideline that the plan uses. If the guideline clearly excludes the procedure, the reviewer has little basis to reverse. Only when the guideline is ambiguous or the patient’s case falls outside the guideline’s scope does the external reviewer have leverage.

Some patient advocates argue that the entire appeals system is designed to exhaust claimants. “The process is a maze with no exit,” said Sarah K. Miller, a healthcare attorney in Portland, Oregon, who has handled hundreds of such cases. “You can win at internal appeal only to lose at external review on the same facts. The guidelines are the wall, and the appeals are just different doors in the same wall.”

What a Transparent Standard Would Look Like

Reform proposals have circulated for years. One approach would create a publicly funded research clearinghouse that evaluates procedure outcomes and publishes evidence summaries that any plan could use, replacing proprietary guidelines with a common standard. The Patient-Centered Outcomes Research Institute (PCORI) already produces such research, but its findings are not formatted as prior-authorization criteria and are not mandatory. Legislation introduced in three states in 2025 and 2026—California, Washington, and Colorado—would require health plans to use state-approved medical necessity criteria rather than proprietary ones, but none has passed.

Another proposal would standardize prior-authorization forms across all carriers, reducing the administrative burden on providers and making it easier to compare denials. The Health Level Seven (HL7) standards body has developed a digital prior-authorization framework, but adoption is voluntary and slow. A 2025 report from the Office of the National Coordinator for Health IT found that only 12 percent of large health plans had implemented the standard.

Industry pushback centers on cost and feasibility. Retooling legacy claims systems to accommodate a new standard would run into the tens of millions for large carriers, according to a 2024 analysis by the Blue Cross Blue Shield Association. Vendors of proprietary guidelines argue that their products are more nimble than a government-run clearinghouse could be, and that competition drives quality. Critics counter that the current system creates perverse incentives: vendors profit from complexity, and carriers benefit from the friction that reduces claim payouts.

Transparency alone would not eliminate disagreements about medical necessity. Reasonable clinicians can review the same evidence and reach different conclusions. But a system in which the rulebooks are public, the edition history is traceable, and the denial rationale is explained in plain language would at least allow patients and providers to understand the basis of a decision—and to challenge it on the merits rather than on the accident of which guideline a plan happens to license.

How Patients and Providers Can Navigate the Gap

Until reform arrives, those facing a dual-denial scenario have limited but practical options. The first step is to request the name and edition of the medical necessity guideline at the time of pre-authorization submission, not after a denial arrives. The surgeon’s office in this case did not learn which edition was used until the denial letter arrived; asking upfront would have allowed them to check the criteria before scheduling the procedure.

If a denial occurs, the provider should immediately request a peer-to-peer review with a physician in the same specialty. Many utilization management firms allow this, but the window is short—often 48 to 72 hours. The surgeon in this case did not request a peer-to-peer review for the first denial, assuming the appeal process would suffice. By the time he called for the second denial, the adjuster had already closed the case. A live conversation with a specialist can sometimes override the algorithm, especially if the reviewing physician has authority to apply clinical judgment.

The appeal letter should cite contradictory language from the other carrier’s guideline, if available. In this case, the surgeon’s office could have pointed out that InterQual required a conservative care trial while MCG classified the procedure as experimental—a contradiction that a reviewer might find unreasonable. Most external review vendors have authority to overturn a denial if the plan’s criteria are applied inconsistently.

Filing a complaint with the state insurance department can also be an escalation lever. Some states have dedicated consumer assistance programs that can intervene with the carrier. The timeline is long, but the threat of regulatory action sometimes prompts a carrier to reconsider. In this case, the patient’s attorney filed a complaint with the Illinois Department of Insurance, and the individual plan agreed to a second external review. That review upheld the denial, but the case is now in mediation.

Ultimately, the gap between two guidelines will persist until the infrastructure that produces them is reformed. Patients and providers can navigate it, but they cannot eliminate it. The best strategy is to assume that a denial is not final, that the guideline edition matters, and that persistence—through peer review, appeal, and regulatory complaint—is the only lever available. However, the system remains opaque, and even persistent efforts may not yield a different outcome. The structural problem—a for-profit guideline system with no public accountability—means that individual cases are resolved not by consistent clinical logic but by the accidental alignment of edition dates and vendor contracts.